FrancophonIA/ELRC3.0 huggingface dataset:
English: Oestrous cycles were affected at doses of 1.1 mg/kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/kg (9 times the maximum human dose).
Maltese: Iċ-ċikli estruwi kienu affettwati b'dożi ta' 1.1 mg/kg (3 darbiet id-doża massima fil bniedem) u l-parametri tar-riproduzzjoni kienu influwenzati fil-firien mogħtija 3 mg/kg (9 darbiet id doża massima fil-bniedem).
English: INFORMATION IN BRAILLE ZYPREXA 15 mg
Maltese: INFORMAZZJONI BIL-BRAILLE ZYPREXA 15 mg
English: 1 mg olanzapine is retained in the vial and syringe, thus allowing delivery of 10mg olanzapine.
Maltese: 1 mg olanzapine tinżamm fil-fjala u fis-siringa, għalhekk tħalli 10 mg ta' olanzapine.
English: < 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Maltese: 5.17 - < 6.2 mmol/l) għal għoljin (≥ 6.2 mmol/l) kienu komuni ħafna.
English: ZYPREXA 20 mg coated tablets are pink.
Maltese: ZYPREXA 20 mg pilloli miksija huma roża.
English: Eli Lilly Sweden AB Tel: + 46 (0)8 7378800
Maltese: Tel: + 46 (0)8 7378800
English: In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr).
Maltese: F'anzjani b'saħħithom (65 u fuqhom) f'paragun ma' pazjenti mhux anzjani, il-half life ta' l eliminazzjoni medja twalet (51.8 paragun ma' 33.8 siegħa) u t-tneħħija tnaqqset (17.5 paragun ma'
English: Each coated tablet contains 20 mg olanzapine.
Maltese: Kull pillola miksija għandha 20 mg olanzapine.
English: There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively).
Maltese: f'pazjenti ttattati b'olanzapine, meta mqabblin ma' pazjenti ttrattati bil-plaċebo (1.3% kontra 0.4%,
English: Excipient with known effect: Each coated tablet conatins 238 mg lactose monohydrate.
Maltese: Kull pillola miksija fiha 238 mg lactose monohydrate
English: INFORMATION IN BRAILLE ZYPREXA 10 mg
Maltese: INFORMAZZJONI BIL-BRAILLE ZYPREXA 10 mg
English: In female versus male subjects administered oral olanzapine the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr).
Maltese: F' pazjenti femminili f'paragun ma' dawk maskili l-medja tal-half life ta' l-eliminazzjoni ġiet kemmxejn mtawla (36.7 kontra 32.3 sigħat) u t-tneħħija tnaqqset (18.9 kontra 27.3 l/hr).
English: Marketing Authorisation Holder Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, L-Olanda.
English: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Maltese: Sensittivita' eċċessiva għas-sustanza attiva jew għal kwalunkwe wieħed mill-eċċipjenti elenkati fis taqsima 6.1.
English: Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l
Maltese: Tibdil fit-trigliċeridi waqt is-sawm mil-limitu tan-normal fil-linja bażi (≥ 1.69 mmol/l- <
English: Each coated tablet contains 15 mg olanzapine.
Maltese: Kull pillola miksija għandha 15 mg olanzapine.
English: A second injection, 5-10 mg, may be administered 2 hours after the first injection on the basis of individual clinical status.
Maltese: It-tieni injezzjoni, 5-10 mg, tista' tingħata sagħtejn wara l-ewwel injezzjoni skond l-istat kliniku individwali.
English: INFORMATION IN BRAILLE ZYPREXA 5 mg
Maltese: INFORMAZZJONI BIL-BRAILLE ZYPREXA 5 mg
English: Excipient with known effect: Each coated tablet contains 156 mg lactose monohydrate.
Maltese: Kull pillola miksija fiha 156 mg lactose monohydrate
English: Each coated tablet contains 10 mg olanzapine.
Maltese: Kull fjala għandha 10 mg olanzapine.
English: A common (≥ 1/100 to < 1/10) undesirable effect associated with the use of intramuscular olanzapine in clinical trials was somnolence.
Maltese: B'mod mhux komuni (≥ 0.1% u < 1%) ġiet irrapportata assoċjazzjoni temporali bejn il-kura b'olanzapine u t- tromboemboliżmu fil-vini.
English: The dose for patients aged over 65 years is 2.5 mg or 5 mg.
Maltese: Id-doża għall-pazjenti 'l fuq minn 65 sena hija 2.5 mg jew 5 mg.
English: ZYPREXA 2.5 mg coated tablets
Maltese: ZYPREXA 2.5 mg pilloli miksija
English: In non-smoking versus smoking subjects (males and females) administered olanzapine intramuscularly the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).
Maltese: F'pazjenti li ma jpejpux f'paragun ma dawk li jpejpu (irġiel u nisa) mogħtija olanzapine ġol-muskoli il medja tal-half life ta' l-eliminazzjoni twalet (38.6 kontra 30.4 sigħat) u l-clearance tnaqqset (18.6 kontra 27.7 l/hr).
English: The recommended initial dose for olanzapine injection is 10 mg, administered as a single intramuscular injection.
Maltese: Id-doża tal-bidu rakkomandata għall-injezzjoni ta' olanzapine hija 10 mg, tingħata bħala injezzjoni intramuskolari.
English: Excipient with known effect: Each coated tablet contains 234 mg lactose monohydrate.
Maltese: Kull pillola miksija fiha 234 mg lactose monohydrate
English: In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).
Maltese: F'pazjenti li ma jpejpux f'paragun ma' dawk li jpejpu (irġiel u nisa) il-medja tal-half life ta' leliminazzjoni kien imtawwal (38.6 kontra 30.4 siegħa) u l-clearance tnaqqset (18.6 kontra 27.7 l/hr).
English: ZYPREXA 20 mg coated tablets Pink, elliptical, coated tablets debossed with “LILLY” and a numeric identicode, “4420”.
Maltese: Pilloli, elliptiċi, roża u miksijin, imnaqqxa b' "LILLY" u b'kodiċi tal-identità numeriku "4420".
English: Warnings and precautions Talk to your doctor or nurse before you are given ZYPREXA Injection
Maltese: Twissijiet u prekawzjonijiet Kellem lit-tabib jew l-infermier tiegħek qabel ma tingħata l-injezzjoni ZYPREXA
English: Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebocontrolled clinical trials (see section 4.8).
Maltese: In-newtropenja kienet rappurtata spiss meta olanzapine u valproate intużaw flimkien (ara taqsima 4.8).
English: Excipient with known effect: Each coated tablet contains 312 mg lactose monohydrate.
Maltese: Kull pillola miksija fiha 312 mg lactose monohydrate
English: Tardive dyskinesia11 Amnesia 9
Maltese: Distonja (tinkludi okuloġirazzjoni)11 Diskineżja tardiva11
English: Type I, 5 ml glass vial.
Maltese: Fjala tal-ħġieġ tat-tip I, ta' 5 ml.
English: In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms.
Maltese: Fi studji kliniċi, id-deterjorament fis-sintomi tal-marda ta'Parkinson u alluċinazzjonijiet kienu rrappurtati b'mod komuni ħafna u aktar ta' spiss milli bil plaċebo (ara taqsima 4.8), u olanzapine ma kienx aktar effettiv mill-plaċebo fit-trattament tas-sintomi psikotiċi.
English: Solution (after reconstitution): 1 hour.
Maltese: Soluzzjoni (wara li tiġi mħallta) : Siegħa.
English: EU/1/96/022/011 - ZYPREXA - 7.5 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/011 - ZYPREXA -7.5 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 20 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola miksija fiha 20 mg olanzapine
English: The following table provides injection volumes for delivering various doses of olanzapine:
Maltese: It-tabella li ġejja tipprovdi volumi ta' injezzjoni biex tagħti dożi varji ta' olanzapine:
English: Patients treated with any antipsychotic medicines, including ZYPREXA, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Maltese: Pazjenti kkurati b'mediċini antipsikotiċi, inkluż ZYPREXA, għandhom ikunu taħt osservazzjoni għal sinjali u sintomi ta' ipergliċemija (bħal polidipsja, polijurja, polifaġja u debbulizza) u pazjenti bid-dijabete mellitus jew li għandhom fatturi ta' riskju għad-dijabete mellitus għandhom jiġu segwiti b'mod regolari f'każ li l-kontroll tal-glukosju jmur għall-agħar.
English: EU/1/96/022/006 - ZYPREXA - 7.5 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/006 - ZYPREXA -7.5 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: EU/1/96/022/029 - ZYPREXA - 2.5 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/029 - ZYPREXA -2.5 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 7.5 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola miksija fiha 7.5mg olanzapine
English: Nervous system disorders Somnolence Dizziness Akathisia6
Maltese: Sonnolenza Sturdament Akatizja6
English: ZYPREXA 5 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4115”.
Maltese: Pilloli, tondi, bojod u miksijin, stampati b' "LILLY" u b'kodiċi tal-identità numeriku "4115".
English: Excipient with known effect: Each coated tablet contains 178 mg lactose monohydrate.
Maltese: Kull pillola miksija fiha 178 mg lactose monohydrate
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 2.5 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola miksija fiha 2.5mg olanzapine
English: Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Maltese: Effetti sekondarji mhux komuni ( jistgħu jaffettwaw sa 1 minn kull 100 persuna) jinkludu sensittività eċċessiva (eż. nefħa fil-ħalq u l-gerżuma, ħakk, raxx);dijabete jew dijabete li tmur għall-agħar, kultant assoċjata ma' ketoaċidożi (ketoni fid-demm u fl-awrina) jew koma; aċċessjonijiet, normalment assoċjati ma' storja ta' aċċessjonijiet (epilessija); ebusija tal-muskoli jew spażmi (inklużi movimenti fl għajnejn); sindrome ta' saqajn irrekwieti; problemi fil-mod kif titkellem; temtim; il-qalb tħabbat bilmod; sensittività għad-dawl tax-xemx; tinfaraġ; nefħa fl-addome; telf tal-memorja jew tibda tinsa; inkontinenza urinarja; nuqqas ta' kapaċità li tgħaddi l-urina; jaqa' x-xagħar; nuqqas ta' jew tnaqqis fil mestrwazzjoni u tibdil fis-sider fl-irġiel u fin-nisa bħal produzzjoni mhux normali ta' ħalib mis-sider jew tkabbir mhux normali.
English: EU/1/96/022/031 - ZYPREXA - 7.5 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/031 - ZYPREXA -7.5 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: 1 vial Powder for solution for injection.
Maltese: Kunjett 1 Trab għal soluzzjoni għall-injezzjoni.
English: Dysarthria Stuttering11
Maltese: kolestatiku jew tattnejn flimkien)11
English: EU/1/96/022/037 - ZYPREXA - 7.5 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/037 - ZYPREXA - 7.5 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: The Cmax occurs earlier after intramuscular compared to oral use (15 to 45 minutes versus 5 to 8 hours).
Maltese: Il-Cmax tintlaħaq qabel b'użu intramuskolari kumparat ma' l-użu mill-ħalq (minn 15 sa 45 minuta kontra 5 sa 8 sigħat).
English: Caution should be exercised in patients who consume alcohol or receive medicinal products that can induce hypotension, bradycardia, respiratory or central nervous system depression (see section 4.4).
Maltese: Għandha tittieħed attenzjoni f'pazjenti li jixorbu l-alkoħol jew li jingħataw prodotti mediċinali li jistgħu jinduċu pressjoni baxxa , bradikardja, tnaqqis fin-nifs jew depressjoni tas-sistema nervuża ċentrali (ara taqsima 4.4).
English: EU/1/96/022/034 - ZYPREXA - 20 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/034 - ZYPREXA -20 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: EU/1/96/022/035 - ZYPREXA - 2.5 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/035 - ZYPREXA - 2.5 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: ZYPREXA 10 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4117”.
Maltese: Pilloli, tondi, bojod u miksijin, stampati b' "LILLY" u b'kodiċi tal-identità numeriku "4117".
English: Each ZYPREXA tablet contains either 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg of the active substance.
Maltese: 7.5 mg, 10 mg, 15 mg jew 20 mg tas-sustanza attiva.
English: In an 18 month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.
Maltese: Fi studju ta' 18-il xhar f'pazjenti b'manija jew b'episodji mħallta stabilizzati fuq olanzapine flimkien ma' stabilizzatur tal-burdata (lithium jew valproate), l-użu fit-tul ta' olanzapine flimkien ma' lithium jew l-valproate ma kienx statistikament sinifikanti superjuri għall-lithium jew għall-valproate waħdu biex jittardja r-rikorrenza bipolari, kif definit skond il-kriterji (dijanjostiċi) tas-sindromu.
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 7.5 mg coated tablets olanzapine
Maltese: ZYPREXA 7.5 mg pilloli miksija Olanzapine
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 7.5 mg coated tablets Olanzapine
Maltese: ZYPREXA 7.5 mg pilloli miksija olanzapine
English: The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Maltese: pressjoni baxxa mal-waqfien, effetti antikolinerġiċi, żieda fil-livelli tal-aminotransferases tal-fwied li ma jurux sintomi u li huma momentanji (ara taqsima 4.4), raxx, astenja, għeja, deni, artralġja, żieda fil-livell tal-alkaline phophatase, livell għoli ta' gamma glutamyltransferase, livell għoli ta' aċtu uriku, livell għoli ta' creatine phosphokinase u edima.
English: EU/1/96/022/025 - ZYPREXA - 7.5 mg - coated tablets - 35 tablets, per box.
Maltese: EU/1/96/022/025 - ZYPREXA -7.5 mg - pilloli miksija - 35 pillola, kull kaxxa.
English: Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and oral in vivo mammalian tests.
Maltese: Mutaġeniċità Olanzapine ma ikkawżatx mutaġeniċità jew klastoġeniċità f'firxa sħiħata' testijiet standard, li nkludew testijiet ta' mutazzjoni tal-mikrobi kif ukoll testijiet fuq il-mammiferi kemm in vitro kif ukoll in vivo.
English: EU/1/96/022/033 - ZYPREXA - 15 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/033 - ZYPREXA -15 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: EU/1/96/022/019 - ZYPREXA - 2.5 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/019 - ZYPREXA -2.5 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: Dementia-related psychosis and/or behavioural disturbances Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Maltese: Olanzapine mhux irrakkomandat għall-użu f'pazjenti b'psikożi relatata mad-demenzja u/jew disturbi fil-komportament, dovut għal żieda fil-mortalità u r-riskju ta' inċident ċerebro-vaskulari.
English: EU/1/96/022/032 - ZYPREXA - 10 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/032 - ZYPREXA -10 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: EU/1/96/022/023 - ZYPREXA - 2.5 mg - coated tablets - 35 tablets, per box.
Maltese: EU/1/96/022/023 - ZYPREXA -2.5 mg - pilloli miksija - 35 pillola, kull kaxxa.
English: EU/1/96/022/040 - ZYPREXA - 20 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/040 - ZYPREXA - 20 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: EU/1/96/022/038 - ZYPREXA - 10 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/038 - ZYPREXA - 10 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: EU/1/96/022/004 - ZYPREXA - 5 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/004 - ZYPREXA -5 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: EU/1/96/022/028 - ZYPREXA - 20 mg - coated tablets - 35 tablets, per box.
Maltese: EU/1/96/022/028 - ZYPREXA -20 mg - pilloli miksija - 35 pillola, kull kaxxa.
English: ZYPREXA 10 mg coated tablets
Maltese: ZYPREXA 10 mg pilloli miksija
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 2.5 mg coated tablets olanzapine
Maltese: ZYPREXA 2.5 mg pilloli miksija Olanzapine
English: ZYPREXA 5 mg coated tablets
Maltese: ZYPREXA 5 mg pilloli miksija
English: EU/1/96/022/012 - ZYPREXA - 15 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/012 - ZYPREXA -15 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: EU/1/96/022/022 - ZYPREXA - 20 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/022 - ZYPREXA -20 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: EU/1/96/022/014 - ZYPREXA - 20 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/014 - ZYPREXA -20 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: EU/1/96/022/021 - ZYPREXA - 15 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/021 - ZYPREXA -15 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: EU/1/96/022/009 - ZYPREXA - 10 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/009 - ZYPREXA -10 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: Simultaneous injection of intramuscular olanzapine and parenteral benzodiazepine is not recommended due to the potential for excessive sedation, cardiorespiratory depression and in very rare cases, death (see sections 4.5 and 6.2).
Maltese: L-injezzjoni ta' olanzapine intramuskolari flimkien ma' benżodijażepini parenterali mhux rrakkomandat minħabba l-possibbiltà ta' sedazzjoni eċċessiva, tnaqqis fil-funzjoni kardjorespiratorja u f'każijiet rari ħafna, mewt (ara taqsimiet 4.5 u 6.2).
English: EU/1/96/022/039 - ZYPREXA - 15 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/039 - ZYPREXA - 15 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 15 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola miksija fiha 15 mg olanzapine
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains 10 mg olanzapine.
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull kunjett fih 10 mg olanzapine.
English: EU/1/96/022/026 - ZYPREXA - 10 mg - coated tablets - 35 tablets, per box.
Maltese: EU/1/96/022/026 - ZYPREXA -10 mg - pilloli miksija - 35 pillola, kull kaxxa.
English: EU/1/96/022/002 - ZYPREXA - 2.5 mg - coated tablets - 28 tablets, per box.
Maltese: EU/1/96/022/002 - ZYPREXA -2.5 mg - pilloli miksija - 28 pillola, kull kaxxa.
English: EU/1/96/022/030 - ZYPREXA - 5 mg - coated tablets - 70 tablets, per box.
Maltese: EU/1/96/022/030 - ZYPREXA -5 mg - pilloli miksija - 70 pillola, kull kaxxa.
English: EU/1/96/022/036 - ZYPREXA - 5 mg - coated tablets - 98 tablets, per box.
Maltese: EU/1/96/022/036 - ZYPREXA - 5 mg - pilloli miksija - 98 pillola, kull kaxxa.
English: Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).
Maltese: 10 mg kuljum f'terapija flimkien ma' xi sustanza oħra (ara taqsima 5.1).
English: For further information on continued treatment with oral olanzapine (5 to 20 mg daily), see the Summary of Product Characteristics for ZYPREXA coated tablets or ZYPREXA VELOTAB orodispersible tablets.
Maltese: Għal aktar tagħrif dwar it-tkomplija tat-trattament b'olanzapine orali (5 sa 20 mg kuljum), ara lKaratteristiċi tal-Prodott fil-Qosor ta' ZYPREXA pilloli miksija jew ZYPREXA VELOTAB pilloli li jinħallu mill-ħalq.
English: EU/1/96/022/027 - ZYPREXA - 15 mg - coated tablets - 35 tablets, per box.
Maltese: EU/1/96/022/027 - ZYPREXA -15 mg - pilloli miksija - 35 pillola, kull kaxxa.
English: EU/1/96/022/020 - ZYPREXA - 5 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/020 - ZYPREXA -5 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: EU/1/96/022/004 28 coated tablets EU/1/96/022/024 35 coated tablets EU/1/96/022/020 56 coated tablets EU/1/96/022/030 70 coated tablets EU/1/96/022/036 98 coated tablets
Maltese: EU/1/96/022/004 28 pillola miksija EU/1/96/022/024 35 pillola miksija EU/1/96/022/020 56 pillola miksija EU/1/96/022/030 70 pillola miksija EU/1/96/022/036 98 pillola miksija
English: NAME OF THE MEDICINAL PRODUCT ZYPREXA 10 mg coated tablets olanzapine
Maltese: ZYPREXA 10 mg pilloli miksija olanzapine
English: EU/1/96/022/014 28 coated tablets EU/1/96/022/028 35 coated tablets EU/1/96/022/022 56 coated tablets EU/1/96/022/034 70 coated tablets EU/1/96/022/040 98 coated tablets
Maltese: EU/1/96/022/014 28 pillola miksija EU/1/96/022/028 35 pillola miksija EU/1/96/022/022 56 pillola miksija EU/1/96/022/034 70 pillola miksija EU/1/96/022/040 98 pillola miksija
English: Potential for interaction following intramuscular injection In a single dose intramuscular study of olanzapine 5 mg, administered 1 hour before intramuscular lorazepam 2 mg (metabolised by glucuronidation), the pharmacokinetics of both medicines were unchanged.
Maltese: Fi studju ta' doża waħda intramuskolari ta' olanzapine 5 mg, li ngħatat siegħa qabel lorazepam 2 mg mgħoti minn ġol-muskoli (metabolizzata b' glukoronidazzjoni), il-komportament farmakokinetiku taż żewġ mediċini ma kinux mibdula.
English: EU/1/96/022/010 - ZYPREXA - 10 mg - coated tablets - 56 tablets, per box.
Maltese: EU/1/96/022/010 - ZYPREXA -10 mg - pilloli miksija - 56 pillola, kull kaxxa.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each coated tablet contains 10 mg olanzapine
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA Kull pillola miksija fiha 10 mg olanzapine
English: The daily dose of ZYPREXA is between 5 mg and 20 mg.
Maltese: Id-doża ta' kuljum ta' ZYPREXA hija bejn 5 mg u 20 mg.
English: ZYPREXA 2.5 mg coated tablets Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4112”.
Maltese: Pilloli, tondi, bojod u miksijin, stampati b' "LILLY" u b'kodiċi tal-identità numeriku "4112".
English: EU/1/96/022/009 28 coated tablets EU/1/96/022/026 35 coated tablets EU/1/96/022/010 56 coated tablets EU/1/96/022/032 70 coated tablets EU/1/96/022/038 98 coated tablets
Maltese: EU/1/96/022/009 28 pillola miksija EU/1/96/022/026 35 pillola miksija EU/1/96/022/010 56 pillola miksija EU/1/96/022/032 70 pillola miksija EU/1/96/022/038 98 pillola miksija
English: EU/1/96/022/01128 coated tablets EU/1/96/022/025 35 coated tablets EU/1/96/022/006 56 coated tablets EU/1/96/022/031 70 coated tablets EU/1/96/022/037 98 coated tablets
Maltese: EU/1/96/022/011 28 pillola miksija EU/1/96/022/025 35 pillola miksija EU/1/96/022/006 56 pillola miksija EU/1/96/022/031 70 pillola miksija EU/1/96/022/037 98 pillola miksija